

**The Drug Utilization Review Board Reviewed the Following
New Drugs and Clinical Reviews on
June 16, 2011**

The Georgia Medicaid Drug Utilization Review (DUR) Board has provided its clinical recommendations for the Department of Community Health's (DCH) to consider in their decisions on the following new drug reviews, therapeutic class review and clinical utilization reviews for the Georgia Medicaid Fee-for-Service Preferred Drug List (PDL).

New Drug Reviews

Oral Contraceptive

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Beyaz*.

Hyperammonemic

The DUR Board recommended *Preferred* status with *Prior Authorization* for *Carbaglu*.

Emergency Contraceptive

The DUR Board voted to table a recommendation until the next Executive Session for *Ella*.

Multiple Sclerosis

The DUR Board voted to table a recommendation until the next Executive Session for *Gilenya*.

Anticoagulant

The DUR Board voted to table a recommendation until the next Executive Session for *Pradaxa*.

Therapeutic Class Review

Alpha-1 Proteinase Inhibitors

The DUR Board recommended *Prior Authorization* for all agents, *Aralast-NP*, *Glassia*, *Prolastin-C* and *Zemaira*. The DUR Board also voted to table a recommendation on step therapy until the next Executive Session.

Clinical Utilization Reviews

Acetaminophen-Containing Combination Products

The DUR Board recommended *No Action* to be taken against *Acetaminophen-Containing Combination Products* with strengths higher than 325mg of acetaminophen per unit during the 3-year phase-out period by the Food and Drug Administration and to continue educating providers through letter and retrospective drug utilization review interventions.

Cough and Cold Products

The DUR Board recommended *Non-Covered* status for all *Cough & Cold Products*.